IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by V Square Quantitative Management LLC

V Square Quantitative Management LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,955 shares of the company’s stock after purchasing an additional 83 shares during the quarter. V Square Quantitative Management LLC’s holdings in IDEXX Laboratories were worth $988,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Riverview Trust Co acquired a new position in shares of IDEXX Laboratories in the 1st quarter valued at $26,000. Crewe Advisors LLC purchased a new position in shares of IDEXX Laboratories in the 1st quarter worth $26,000. Ridgewood Investments LLC acquired a new position in IDEXX Laboratories in the second quarter valued at $27,000. Institutional & Family Asset Management LLC purchased a new stake in IDEXX Laboratories during the second quarter valued at about $28,000. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in IDEXX Laboratories during the second quarter worth about $36,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $457.74 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. The company has a market capitalization of $37.80 billion, a price-to-earnings ratio of 44.31, a price-to-earnings-growth ratio of 4.14 and a beta of 1.33. The firm’s fifty day moving average price is $487.50 and its 200 day moving average price is $491.76.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The firm’s revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.67 earnings per share. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Piper Sandler reduced their price objective on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. JPMorgan Chase & Co. reduced their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. BTIG Research began coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Finally, StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $574.13.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.